Japan lipid lowering drugs market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The increase in heart disease cases, higher awareness of the health risks associated with high cholesterol levels, and the availability of effective treatments are key factors driving the global market for lipid-lowering pharmaceuticals. The major key players in this market are Sanofi, Sun Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Novartis AG, AbbVie Inc., Merck & Co. Inc., Amgen Inc., and Dr. Reddy's.
Japan Lipid Lowering Drugs Market is valued at around $1962.9 Mn in 2022 and is projected to reach $2749 Mn by 2030, exhibiting a CAGR of 4.3% during the forecast period 2023-2030.
A molecule that resembles fat called cholesterol is found in the blood and aids in the production of hormones, vitamin D, and other compounds that aid in food digestion. The synthesis of cholesterol in the body is assisted by the liver and intestines as well as foods consumed such as eggs, fish, meat, and others.
There are 2 types of cholesterol:
Additionally, a rise in high cholesterol increases the risk of heart disease by causing fatty deposits to form in blood vessels. Although the body needs cholesterol, levels more than 240 mg/dl are regarded to be high cholesterol and can interfere with the body's ability to operate normally. A poor diet, hereditary conditions, type 2 diabetes, renal disease, and other conditions can all contribute to high cholesterol.
The few classes of drugs used as lipid lowering drugs are:
The increase in heart disease cases, higher awareness of the health risks associated with high cholesterol levels, and the availability of effective treatments are key factors driving the global market for lipid-lowering pharmaceuticals. The major key players in this market are Sanofi, Sun Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Novartis AG, AbbVie Inc., Merck & Co. Inc., Amgen Inc., and Dr. Reddy's.
Market Growth Drivers
The ageing of the population, rising rates of high cholesterol, increased demand for medications that lower cholesterol, management and treatment of cholesterol, among other reasons, are all having an effect on the market's growth. In addition, lack of exercise, a shift in lifestyle, consumption of trans and saturated fats, smoking, and other issues are key drivers of market expansion.
Key Players
In March 2023, the US Food and Drug Administration (FDA) has authorised the extended use of Regeneron Pharmaceuticals, Inc.'s Evkeeza medication in children aged 5 to 11 years to treat an extremely rare condition that raises cholesterol levels.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Drugs Class
By Indications
By End Users
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.